© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 13, 998-1007,
July 4, 2001
© 2001 Oxford University Press
Inhibition of Murine Prostate Tumor Growth and Activation of Immunoregulatory Cells With Recombinant Canarypox Viruses
Affiliations of authors: T. S. Griffith, J. Tian, W. Zhao, T. L. Ratliff, Department of Urology, University of Iowa, Iowa City; M. Kawakita, Department of Urology, Faculty of Medicine, Kyoto University, Japan; J. Ritchey, Washington University, St. Louis, MO; J. Tartaglia, Aventis Pasteur, Toronto, ON, Canada; I. Sehgal, T. C. Thompson, Scott Department of Urology, Baylor College of Medicine, Houston, TX.
Correspondence to: Thomas S. Griffith, Ph.D., Department of Urology, University of Iowa, 200 Hawkins Dr., 428 MRC, Iowa City, IA 52242–1089 (e-mail: thomas-griffith{at}uiowa.edu).
Background: Immunization with modified tumor cells carrying recombinant immunomodulatory genes is being explored as cancer immunotherapy. In this study, we examine whether canarypox ALVAC viruses carrying immunostimulatory cytokine genes (granulocyte–macrophage colony-stimulating factor, interleukin 2, interleukin 12, and tumor necrosis factor-
) can induce antitumor immunity (to rechallenge) in the RM-1 model of a highly aggressive, weakly immunogenic murine prostate cancer. Methods: For antitumor activity studies, RM-1 murine prostate cancer cells were infected with the parental ALVAC virus or one or two recombinant ALVAC–cytokine viruses and then injected into male C57BL/6 mice. For rechallenge studies, other mice were first given an injection subcutaneously with irradiated (nonproliferating) recombinant ALVAC-infected RM-1 cells and then (10 days later) with untreated RM-1 cells. For the determination of which immune cells were required for antitumor activity, mice were immunodepleted of CD4, CD8, or natural killer (NK) NK1.1 cells with the corresponding monoclonal antibodies and were then given an injection of ALVAC–cytokine-infected RM-1 cells. For all experiments, tumor outgrowth and animal survival were monitored. Results: After subcutaneous injection into mice, RM-1 cells infected with one (except ALVAC–interleukin 2) or two ALVAC–cytokine recombinants had statistically significantly greater antitumor activity than RM-1 cells infected with parental ALVAC (P<.001 for all; two-sided test). The antitumor activity of RM-1 cells infected with any two ALVAC–cytokine recombinants was greater than, but not statistically significantly different from, that of RM-1 cells infected with any one ALVAC–cytokine recombinant. NK1.1 cells were necessary for antitumor activity, but tumor-specific CD4+ regulatory T cells were also induced that inhibited CD8+ RM-1-specific cytotoxic T cells, resulting in the lack of immunity to a rechallenge by RM-1 cells. Discussion: Canarypox viruses can transfer immunostimulatory cytokine genes into RM-1 prostate cancer cells. When such cells were injected into mice, the cytokines induced an antitumor response against this highly aggressive, weakly immunogenic tumor. This response, however, did not protect the mouse against a rechallenge with RM-1 cells because suppressor CD4+ T cells were induced that inhibited tumor-specific CD8+ cytotoxic T cells.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Mukhopadhaya, J. Mendecki, X. Dong, L. Liu, S. Kalnicki, M. Garg, A. Alfieri, and C. Guha Localized Hyperthermia Combined with Intratumoral Dendritic Cells Induces Systemic Antitumor Immunity Cancer Res., August 15, 2007; 67(16): 7798 - 7806. [Abstract] [Full Text] [PDF]
|
|